Overview

A Bioequivalence Study Comparing a Single 1.5mL Dose of Brodalumab vs. Two Doses (1.0mL + 0.5mL) of Brodalumab

Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
A healthy subject, 2-way cross-over study to evaluate the bioequivalence of a single dose of Brodalumab vs. two doses of Brodalumab
Phase:
Phase 1
Details
Lead Sponsor:
Amgen
Bausch Health Americas, Inc.
Treatments:
Brodalumab